Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
Vaxart's Two Newest Independent Directors James Breitmeyer, M.D., Ph.D., and Kevin Finney Send Letter to Shareholders Ahead of 2026 Annual Meeting
Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
Vaxart to Participate in BTIG Infectious Disease Day 2026
Vaxart Urges Shareholders to Vote “FOR” ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders
Vaxart Files Preliminary Proxy Statement and Issues Open Letter to Shareholders
Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript
Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
Vaxart to Host Stockholder Fireside Chat on May 8 at 4:30 p.m. ET
Vaxart (OTCMKTS:VXRT) Stock Passes Above 50-Day Moving Average – Time to Sell?
Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors
Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital
Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript
Vaxart, Inc. (VXRT) Q4 2025 Earnings Call Transcript
Vaxart to Host Upcoming Conference Calls
3 Stocks Under $5 With Strong Analyst Upside Potential
Vaxart (OTCMKTS:VXRT) Stock Price Passes Above Fifty Day Moving Average – What’s Next?
Hagens Berman Sobol Shapiro LLP and Scott+Scott Attorneys at Law LLP Announce a Class Action for All Vaxart Shareholders that May Include You, Even if You Participated in the Previous Partial Settlement with Vaxart
The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)
Vaxart to Participate in the Global BioInnovation Forum on January 13, 2026
Vaxart (NASDAQ:VXRT) Shares Cross Below 200-Day Moving Average – Time to Sell?
Vaxart, Inc. (VXRT) Shareholder/Analyst Call Transcript
Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript
Vaxart to Host Upcoming Conference Calls
Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program
Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025
Vaxart Appoints W. Mark Watson as Lead Independent Director
Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate
Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting
Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.
Concerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board Accountability
Concerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder Rights
Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript
VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates
US orders Vaxart to stop COVID-19 trial amid mRNA wind down
Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq
OTC Markets Group Welcomes Vaxart, Inc. to OTCQX
Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
Vaxart Reports Positive Clinical Data Demonstrating that its Second-Generation Vaccine Technology Produces Much Stronger Antibody Responses than its First-Generation Technology
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
Vaxart Announces Adjournment of Annual Meeting of Stockholders
Vaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025
Vaxart's Founder and Chief Scientific Officer Provides Video Update to Stockholders
Vaxart Answers Additional Frequently Asked Questions from Retail Investors
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
Vaxart Announces Adjournment of Annual Meeting of Stockholders